Loading clinical trials...
Loading clinical trials...
Immunogenicity and Safety of GSK Biological's DTPa-HBV-IPV/Hib Vaccine or DTPa-IPV/Hib Co-administered With HBV Vaccine as Primary and Booster Vaccination in Healthy Infants Born to Hepatitis B Surface Antigen Negative Mothers
Conditions
Interventions
DTPa-HBV-IPV/Hib vaccine
DTPa-IPV/Hib vaccine
+1 more
Start Date
January 1, 2001
Primary Completion Date
November 1, 2002
Completion Date
November 1, 2002
Last Updated
September 7, 2016
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions